×
Request Free Sample ×
Whole Exome Sequencing Market Research Report - Global Forecast till 2035 Infographic

Kindly complete the form below to receive a free sample of this Report

* Please use a valid business email

Leading companies partner with us for data-driven Insights

clients tt-cursor
Hero Background

Whole Exome Sequencing Market

ID: MRFR/HC/7291-CR
164 Pages
Kinjoll Dey
May 2020

Whole Exome Sequencing Market Research Report Information By Product (Kits, Systems, And Services), By Technology (Sequencing by Synthesis (SBS) And ION Semiconductor Sequencing), By Application (Diagnostics, Drug Discovery and development, And Agriculture and Animal Research), By End-User (Research Centers and Government Institutes, Hospitals and Diagnostics Centers And Pharmaceuticals & Biotechnology Companies), And By Region (North America, Europe, Asia-Pacific, And Rest Of The World) –Market Forecast Till 2035

Share:
Download PDF ×

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

Whole Exome Sequencing Market Infographic
×
Whole Exome Sequencing Market Infographic Full View
Purchase Options
Compare License
Summary Table of Contents Segmentation Download PDF

Whole Exome Sequencing Market Summary

As per MRFR analysis, the Whole Exome Sequencing Market Size was estimated at 2163.64 USD Million in 2024. The Whole Exome Sequencing industry is projected to grow from 2600.73 in 2025 to 16376.23 by 2035, exhibiting a compound annual growth rate (CAGR) of 20.2 during the forecast period 2025 - 2035.

Key Market Trends & Highlights

The Whole Exome Sequencing Market is poised for substantial growth driven by technological advancements and increasing demand for personalized medicine.

  • North America remains the largest market for whole exome sequencing, driven by robust healthcare infrastructure and research capabilities.
  • The Asia-Pacific region is emerging as the fastest-growing market, fueled by increasing investments in healthcare and biotechnology.
  • Clinical diagnostics represent the largest segment, while personalized medicine is the fastest-growing segment, reflecting shifting healthcare paradigms.
  • Key market drivers include the rising incidence of genetic disorders and supportive government initiatives promoting genetic testing.

Market Size & Forecast

2024 Market Size 2163.64 (USD Million)
2035 Market Size 16376.23 (USD Million)
CAGR (2025 - 2035) 20.2%

Major Players

Illumina (US), Thermo Fisher Scientific (US), Agilent Technologies (US), BGI Genomics (CN), Roche (CH), QIAGEN (DE), PerkinElmer (US), F. Hoffmann-La Roche (CH), Macrogen (KR)

Whole Exome Sequencing Market Trends

The Whole Exome Sequencing Market is currently experiencing a transformative phase, driven by advancements in genomic technologies and an increasing emphasis on personalized medicine. As healthcare systems globally recognize the potential of exome sequencing in diagnosing genetic disorders, the demand for these services is on the rise. This trend is further supported by the growing number of research initiatives aimed at understanding the genetic basis of diseases, which in turn fuels the need for comprehensive genomic analysis. Moreover, the integration of artificial intelligence and machine learning in data interpretation is enhancing the efficiency and accuracy of exome sequencing, making it more accessible to a broader range of healthcare providers. In addition to technological advancements, the Whole Exome Sequencing Market is influenced by regulatory frameworks that are evolving to accommodate the rapid pace of innovation. Governments and health organizations are increasingly focusing on establishing guidelines that ensure the ethical use of genetic data while promoting research and development. This regulatory support is likely to foster a conducive environment for market growth. Furthermore, collaborations between academic institutions and biotechnology companies are expected to accelerate the development of novel applications for exome sequencing, thereby expanding its utility in clinical settings. Overall, the Whole Exome Sequencing Market appears poised for substantial growth in the coming years, driven by a confluence of technological, regulatory, and collaborative factors.

Technological Advancements

The Whole Exome Sequencing Market is witnessing rapid technological progress, particularly in sequencing platforms and data analysis tools. Innovations in next-generation sequencing technologies are enhancing throughput and reducing costs, making exome sequencing more accessible to various healthcare settings. Additionally, advancements in bioinformatics are improving the interpretation of complex genomic data, thereby facilitating more accurate diagnoses and personalized treatment plans.

Regulatory Developments

Regulatory frameworks surrounding genetic testing are evolving to keep pace with advancements in the Whole Exome Sequencing Market. Governments and health authorities are increasingly establishing guidelines that promote ethical practices while ensuring patient safety. This regulatory support is likely to encourage the adoption of exome sequencing in clinical practice, as healthcare providers seek to comply with emerging standards.

Collaborative Research Initiatives

Collaborations between academic institutions, research organizations, and biotechnology firms are becoming more prevalent in the Whole Exome Sequencing Market. These partnerships aim to leverage collective expertise and resources to explore novel applications of exome sequencing. Such initiatives are expected to drive innovation and expand the market's potential, as new discoveries emerge from collaborative research efforts.

Whole Exome Sequencing Market Drivers

Market Growth Projections

The Global Whole Exome Sequencing Market Industry is projected to experience substantial growth in the coming years. With a market value of 2.16 USD Billion in 2024, it is anticipated to reach 16.4 USD Billion by 2035, reflecting a remarkable compound annual growth rate of 20.23% from 2025 to 2035. This growth trajectory indicates a robust demand for whole exome sequencing services, driven by advancements in technology, increasing applications in various fields, and supportive government initiatives. The market's expansion is likely to reshape the landscape of genetic testing, making whole exome sequencing an integral component of modern healthcare.

Growing Applications in Oncology

The application of whole exome sequencing in oncology is a significant driver for the Global Whole Exome Sequencing Market Industry. As cancer research progresses, the ability to identify specific genetic mutations associated with various cancers allows for tailored treatment strategies. Whole exome sequencing aids in the discovery of novel biomarkers, which can lead to the development of targeted therapies. This trend is particularly evident in precision oncology, where understanding the genetic landscape of tumors enhances treatment efficacy. The increasing focus on personalized cancer therapies is likely to contribute to the market's growth trajectory in the coming years.

Rising Demand for Genetic Testing

The Global Whole Exome Sequencing Market Industry experiences a surge in demand for genetic testing, driven by the increasing prevalence of genetic disorders and the need for personalized medicine. As healthcare systems worldwide prioritize precision medicine, whole exome sequencing becomes a pivotal tool in identifying genetic mutations. In 2024, the market is valued at approximately 2.16 USD Billion, reflecting a growing recognition of the importance of genetic insights in clinical decision-making. This trend is expected to continue, with projections indicating a market expansion to 16.4 USD Billion by 2035, highlighting the critical role of whole exome sequencing in modern healthcare.

Government Initiatives and Funding

Government initiatives and funding play a crucial role in advancing the Global Whole Exome Sequencing Market Industry. Various countries are investing in genomic research and infrastructure to promote the integration of genetic testing into routine clinical practice. For instance, national health programs are increasingly supporting initiatives that facilitate access to whole exome sequencing for patients with rare diseases. Such investments not only enhance research capabilities but also encourage collaboration between public and private sectors. As governments recognize the potential of genomics in improving healthcare outcomes, the market is poised for substantial growth, driven by supportive policies and funding.

Increasing Awareness and Education

Increasing awareness and education regarding the benefits of whole exome sequencing significantly influence the Global Whole Exome Sequencing Market Industry. Healthcare professionals and patients alike are becoming more informed about the advantages of genetic testing in disease prevention and management. Educational campaigns and resources provided by healthcare organizations contribute to a better understanding of how whole exome sequencing can impact patient care. This heightened awareness is likely to drive demand for genetic testing services, as individuals seek proactive approaches to their health. Consequently, the market is expected to expand as more stakeholders recognize the value of genomic insights.

Technological Advancements in Sequencing Techniques

Advancements in sequencing technologies significantly propel the Global Whole Exome Sequencing Market Industry. Innovations such as next-generation sequencing (NGS) enhance the speed and accuracy of exome sequencing, making it more accessible and cost-effective. These technological improvements not only reduce the time required for sequencing but also increase the throughput of genetic data analysis. As a result, healthcare providers are more inclined to adopt whole exome sequencing as a standard practice in diagnostics. The anticipated compound annual growth rate of 20.23% from 2025 to 2035 underscores the transformative impact of these advancements on the market.

Market Segment Insights

By Application: Clinical Diagnostics (Largest) vs. Personalized Medicine (Fastest-Growing)

In the Whole Exome Sequencing Market, the application segment is primarily dominated by Clinical Diagnostics, which captures a substantial share due to the rising demand for genomic testing in healthcare settings. Research and Development, Drug Discovery, and Personalized Medicine are also significant, but they occupy comparatively smaller portions of the market, reflecting the growing diversification of applications for exome sequencing in modern medicine. Each of these applications plays a vital role in advancing our understanding of genetic diseases and the development of targeted therapies. The growth trends in this segment are driven by an increasing focus on precision medicine, where exome sequencing contributes to tailored treatment solutions. Personalized Medicine is rapidly emerging as a key driver, leveraging advances in technology and decreasing sequencing costs. Research and Development initiatives continue to expand, enabling novel drug discovery processes through comprehensive genetic insights. The interplay of these trends positions the Whole Exome Sequencing Market for sustained growth, with each segment contributing uniquely to the overarching landscape of genomic medicine.

Clinical Diagnostics (Dominant) vs. Personalized Medicine (Emerging)

Clinical Diagnostics stands out as the dominant application in the Whole Exome Sequencing Market, primarily due to its crucial role in identifying genetic disorders and informing treatment protocols. This segment benefits from regulatory support and increasing adoption in clinical settings, thus ensuring its leading position. On the other hand, Personalized Medicine is emerging as a transformative force, harnessing the power of whole exome sequencing to tailor healthcare solutions to individual genetic profiles. As technology advances and costs decrease, the potential for Personalized Medicine to deliver targeted therapies grows, attracting significant investments. Both segments are critical to advancing genomic research, but while Clinical Diagnostics focuses on immediate healthcare applications, Personalized Medicine aims for innovative, long-term treatment strategies.

By End Use: Hospitals (Largest) vs. Research Institutes (Fastest-Growing)

The Whole Exome Sequencing Market is characterized by distinct contributions from its end-use segments. Hospitals constitute the largest share, driven by their critical role in clinical diagnostics and patient management. Their extensive funding and access to cutting-edge technologies position them at the forefront of the market. In contrast, research institutes contribute significantly, sustaining their positioning through innovative research and collaborations. This diversity in end-use highlights the adaptability of whole exome sequencing technologies across different environments.

End-Use: Hospitals (Dominant) vs. Research Institutes (Emerging)

Hospitals have emerged as the dominant force in the Whole Exome Sequencing Market due to their expansive infrastructure, capacity for large-scale genomic testing, and integration into patient care strategies. They utilize whole exome sequencing for various clinical applications, contributing significantly to improved patient outcomes. On the other hand, research institutes are regarded as an emerging player, rapidly gaining ground through their focus on genomic research and development of new sequencing techniques. Their innovative environment fosters advancements in exome sequencing, attracting funding and partnerships that enhance their market relevance.

By Technology: Next Generation Sequencing (Largest) vs. Sanger Sequencing (Fastest-Growing)

In the Whole Exome Sequencing Market, Next Generation Sequencing (NGS) has emerged as the dominant technology due to its capability to process massive amounts of data rapidly and cost-effectively. Sanger Sequencing, although traditional and regarded for its accuracy, has seen a decline as NGS technology has revolutionized genetic analysis. Microarray Technology, while still utilized for certain applications, holds a smaller portion of the market compared to these two. As the whole exome sequencing arena continues to evolve, the demand for high-throughput sequencing provided by NGS is pushing innovation and new technological advancements. Meanwhile, Sanger Sequencing is experiencing a resurgence as a complementary technology, especially for validation purposes. Microarray Technology is increasingly being integrated into larger workflows, but it remains overshadowed by the efficiencies of NGS.

Technology: Next Generation Sequencing (Dominant) vs. Sanger Sequencing (Emerging)

Next Generation Sequencing dominates the Whole Exome Sequencing Market due to its unparalleled efficiency, scalability, and ability to generate vast amounts of genomic data within a short time. It is particularly favored for applications requiring in-depth genetic analysis, such as cancer genomics and rare genetic disorders. In contrast, Sanger Sequencing, once the gold standard, is now emerging as a specialized solution for targeted sequencing applications and confirmatory testing. While it may lack the throughput of NGS, Sanger Sequencing offers high accuracy and reliability, making it a vital tool in diagnostic settings and research. Together, these technologies exemplify a synergistic approach in genetic research and clinical applications.

By Product Type: Consumables (Largest) vs. Instruments (Fastest-Growing)

In the Whole Exome Sequencing Market, consumables constitute the largest segment, capturing a significant share of overall market revenue. These consumables include reagents, kits, and various essential components necessary for effective sequencing. Instruments, on the other hand, represent a rapidly expanding segment, driven by advancements in technology and the increasing demand for high-throughput sequencing. As such, the performance and reliability of these instruments are critical in determining their market position. The growth trends within the Whole Exome Sequencing Market are largely propelled by innovations in sequencing technology and a rising emphasis on precision medicine. The demand for instruments is notably increasing as laboratories seek to enhance their capabilities and throughput. Furthermore, the growing prevalence of genetic disorders and an expanding application scope of whole exome sequencing in research and clinical settings are contributing to an accelerated uptake of both consumables and instruments.

Consumables: Dominant vs. Instruments: Emerging

Consumables play a dominant role in the Whole Exome Sequencing Market due to their essential nature in the sequencing process. They encompass a range of products such as DNA extraction kits, library preparation tools, and sequencing reagents that are crucial for proper sample processing. The demand for these items is driven by their frequent usage in various research projects and clinical applications, making them a staple purchase. Instruments, while currently an emerging segment, are gaining traction thanks to technological improvements that enhance the efficiency and accuracy of sequencing. As laboratories upgrade their systems, the transition to more advanced instruments will likely elevate their market position, but they will need to continue innovating to keep pace with the demands of the expanding market.

By Service Type: Data Analysis Services (Largest) vs. Sample Preparation Services (Fastest-Growing)

In the Whole Exome Sequencing Market, Data Analysis Services account for the largest share, reflecting their crucial role in interpreting complex genomic data. Meanwhile, Sample Preparation Services have emerged as a fast-growing segment, driven by increasing demand for high-quality sample processing and preparation techniques. Consultation Services, while essential, hold a smaller market share compared to these two prominent segments.

Data Analysis Services (Dominant) vs. Sample Preparation Services (Emerging)

Data Analysis Services dominate the Whole Exome Sequencing Market by providing essential data interpretation tools and services that researchers and clinicians rely on. These services include bioinformatics and statistical analysis, which are critical for making sense of extensive genomic data. In contrast, Sample Preparation Services are rapidly gaining traction as the demand for optimized and reliable sample processing methods grows. Their importance in ensuring the quality of sequencing results makes them an emerging force, with innovative techniques and technologies being developed to improve efficiency and outcomes in genomic research.

Get more detailed insights about Whole Exome Sequencing Market
Request Free Sample

Regional Insights

North America : Market Leader in Innovation

North America continues to lead the Whole Exome Sequencing market, holding a significant share of 1080.0M in 2024. The region's growth is driven by advanced healthcare infrastructure, increasing investments in genomics, and a rising prevalence of genetic disorders. Regulatory support from agencies like the FDA further catalyzes innovation and adoption of exome sequencing technologies, enhancing research and clinical applications. The competitive landscape is robust, with key players such as Illumina, Thermo Fisher Scientific, and Agilent Technologies dominating the market. The U.S. is the primary contributor, supported by a strong presence of biotechnology firms and research institutions. This concentration of expertise fosters collaboration and accelerates advancements in whole exome sequencing, ensuring North America's continued leadership in the global market.

Europe : Emerging Market with Growth Potential

Europe's Whole Exome Sequencing market is valued at 600.0M, reflecting a growing interest in personalized medicine and genomics. The region benefits from supportive regulatory frameworks and funding initiatives aimed at enhancing genomic research. Countries like Germany and the UK are at the forefront, with increasing investments in healthcare technologies and a focus on precision medicine driving demand for exome sequencing solutions. The competitive environment features prominent players such as QIAGEN and Roche, alongside emerging biotech firms. The European market is characterized by collaborations between academia and industry, fostering innovation. As regulatory bodies emphasize the importance of genomic data in healthcare, Europe is poised for significant growth in the whole exome sequencing sector.

Asia-Pacific : Rapidly Growing Market Segment

The Asia-Pacific region, with a market size of 400.0M, is witnessing rapid growth in whole exome sequencing, driven by increasing healthcare expenditure and advancements in genomic technologies. Countries like China and Japan are leading the charge, supported by government initiatives aimed at enhancing genomic research and healthcare capabilities. The rising prevalence of genetic disorders and a growing focus on personalized medicine are further propelling market demand. The competitive landscape is evolving, with key players such as BGI Genomics and Macrogen making significant strides. The region's market is characterized by a mix of established companies and startups, fostering innovation and collaboration. As the regulatory environment becomes more favorable, Asia-Pacific is set to become a major player in The Whole Exome Sequencing.

Middle East and Africa : Emerging Market with Challenges

The Middle East and Africa (MEA) region, with a market size of 83.64M, is gradually emerging in the whole exome sequencing landscape. The growth is primarily driven by increasing awareness of genetic testing and the rising prevalence of hereditary diseases. However, challenges such as limited healthcare infrastructure and regulatory hurdles hinder rapid market expansion. Governments are beginning to recognize the importance of genomics in healthcare, which may catalyze future growth. Countries like South Africa and the UAE are leading the way in adopting genomic technologies, supported by initiatives aimed at improving healthcare access. The competitive landscape is still developing, with a few key players beginning to establish a foothold. As investments in healthcare infrastructure increase, the MEA region is expected to see gradual growth in the whole exome sequencing market.

Whole Exome Sequencing Market Regional Image

Key Players and Competitive Insights

The Whole Exome Sequencing Market is currently characterized by a dynamic competitive landscape, driven by advancements in genomic technologies and increasing demand for personalized medicine. Key players such as Illumina (US), Thermo Fisher Scientific (US), and BGI Genomics (CN) are at the forefront, each adopting distinct strategies to enhance their market positioning. Illumina (US) focuses on innovation through continuous development of next-generation sequencing technologies, while Thermo Fisher Scientific (US) emphasizes strategic partnerships to expand its product offerings. BGI Genomics (CN) is leveraging its cost-effective solutions to penetrate emerging markets, thereby shaping a competitive environment that is increasingly collaborative yet fiercely competitive.The market structure appears moderately fragmented, with several players vying for market share. Key business tactics include localizing manufacturing to reduce costs and optimize supply chains, which is particularly relevant in the context of global economic fluctuations. The collective influence of these major companies fosters a competitive atmosphere where innovation and operational efficiency are paramount.

In November Illumina (US) announced a partnership with a leading healthcare provider to integrate its sequencing technology into routine clinical practice. This strategic move is likely to enhance patient access to genomic testing, thereby solidifying Illumina's position as a leader in the market. The partnership underscores the growing trend of integrating genomic data into healthcare systems, which could potentially revolutionize patient care.

In October Thermo Fisher Scientific (US) launched a new exome sequencing platform designed to streamline workflows and improve data accuracy. This development is significant as it not only enhances the company's product portfolio but also addresses the increasing demand for high-throughput sequencing solutions. By focusing on technological advancements, Thermo Fisher is positioning itself to capture a larger share of the market.

In September BGI Genomics (CN) expanded its operations into Southeast Asia, establishing a new facility aimed at increasing its production capacity. This expansion is indicative of BGI's strategy to capitalize on the growing demand for affordable genomic solutions in emerging markets. By localizing its operations, BGI is likely to enhance its competitive edge and respond more effectively to regional market needs.

As of December current trends in the Whole Exome Sequencing Market are heavily influenced by digitalization, sustainability, and the integration of artificial intelligence (AI) into genomic research. Strategic alliances among key players are shaping the landscape, fostering innovation and collaboration. The competitive differentiation is expected to evolve, shifting from price-based competition to a focus on technological advancements, reliability in supply chains, and the ability to deliver personalized solutions. This transition suggests that companies that prioritize innovation and strategic partnerships will likely emerge as leaders in the market.

Key Companies in the Whole Exome Sequencing Market include

Industry Developments

  • Q2 2024: Illumina Appoints Jacob Thaysen as Chief Executive Officer Illumina, a leading provider of whole exome sequencing solutions, announced the appointment of Jacob Thaysen as CEO, signaling a new phase of leadership for the company’s genomics and sequencing business.
  • Q1 2024: Thermo Fisher Scientific Launches Ion Torrent Genexus System for Clinical Exome Sequencing Thermo Fisher Scientific introduced the Ion Torrent Genexus System, a fully integrated next-generation sequencing platform designed to streamline clinical exome sequencing workflows for hospitals and diagnostic labs.
  • Q2 2024: Roche Receives CE-IVD Mark for AVENIO Tumor Tissue Comprehensive Genomic Profiling Kit Roche announced that its AVENIO Tumor Tissue CGP Kit, which includes whole exome sequencing capabilities, received CE-IVD approval, enabling its use in clinical diagnostics across Europe.
  • Q2 2024: Agilent Technologies Launches SureSelect Human All Exon V9 for Enhanced Exome Sequencing Agilent Technologies released the SureSelect Human All Exon V9, a new exome enrichment solution designed to improve coverage and accuracy for whole exome sequencing applications.
  • Q1 2024: BGI Genomics Expands Clinical Sequencing Lab in Europe BGI Genomics opened a new clinical sequencing laboratory in Copenhagen, Denmark, to increase its capacity for whole exome and genome sequencing services in the European market.
  • Q2 2024: Eurofins Launches Clinical Exome Sequencing Service for Rare Disease Diagnosis Eurofins Scientific announced the launch of a new clinical exome sequencing service aimed at accelerating the diagnosis of rare genetic disorders in Europe and North America.
  • Q1 2024: QIAGEN and Illumina Announce Partnership to Integrate QIAGEN’s Bioinformatics with Illumina Sequencers QIAGEN and Illumina entered a strategic partnership to integrate QIAGEN’s bioinformatics solutions with Illumina’s sequencing platforms, enhancing data analysis for whole exome sequencing workflows.
  • Q2 2024: Oxford Nanopore Technologies Launches New Exome Sequencing Kit for Long-Read Applications Oxford Nanopore Technologies introduced a new exome sequencing kit optimized for long-read sequencing, enabling more comprehensive variant detection in clinical and research settings.
  • Q1 2024: Novogene Opens New Sequencing Facility in Singapore Novogene, a global provider of whole exome sequencing services, inaugurated a new high-throughput sequencing facility in Singapore to serve the Asia-Pacific region.
  • Q2 2024: Myriad Genetics Receives FDA Clearance for Exome-Based Hereditary Cancer Test Myriad Genetics announced FDA clearance for its new exome-based hereditary cancer test, expanding its portfolio of clinical genetic testing solutions.
  • Q1 2024: Pacific Biosciences Launches Revio System for High-Throughput Exome Sequencing Pacific Biosciences launched the Revio System, a new sequencing platform designed to deliver high-throughput and high-accuracy whole exome sequencing for research and clinical applications.
  • Q2 2024: Roche and Genentech Announce Collaboration with UCSF for Large-Scale Exome Sequencing Study Roche and Genentech partnered with the University of California, San Francisco to conduct a large-scale whole exome sequencing study aimed at identifying novel genetic drivers of neurodegenerative diseases.

Future Outlook

Whole Exome Sequencing Market Future Outlook

The Whole Exome Sequencing Market is projected to grow at a 20.2% CAGR from 2024 to 2035, driven by advancements in genomics, increasing demand for personalized medicine, and technological innovations.

New opportunities lie in:

  • Development of integrated bioinformatics platforms for data analysis.
  • Expansion of direct-to-consumer exome sequencing services.
  • Partnerships with pharmaceutical companies for drug development based on genetic insights.

By 2035, the Whole Exome Sequencing Market is expected to be a pivotal component of precision medicine.

Market Segmentation

Whole Exome Sequencing Market End Use Outlook

  • Hospitals
  • Research Institutes
  • Pharmaceutical Companies
  • Diagnostic Laboratories

Whole Exome Sequencing Market Technology Outlook

  • Next Generation Sequencing
  • Sanger Sequencing
  • Microarray Technology

Whole Exome Sequencing Market Application Outlook

  • Clinical Diagnostics
  • Research and Development
  • Drug Discovery
  • Personalized Medicine

Whole Exome Sequencing Market Product Type Outlook

  • Consumables
  • Instruments
  • Software

Whole Exome Sequencing Market Service Type Outlook

  • Data Analysis Services
  • Consultation Services
  • Sample Preparation Services

Report Scope

MARKET SIZE 20242163.64(USD Million)
MARKET SIZE 20252600.73(USD Million)
MARKET SIZE 203516376.23(USD Million)
COMPOUND ANNUAL GROWTH RATE (CAGR)20.2% (2025 - 2035)
REPORT COVERAGERevenue Forecast, Competitive Landscape, Growth Factors, and Trends
BASE YEAR2024
Market Forecast Period2025 - 2035
Historical Data2019 - 2024
Market Forecast UnitsUSD Million
Key Companies ProfiledIllumina (US), Thermo Fisher Scientific (US), Agilent Technologies (US), BGI Genomics (CN), Roche (CH), QIAGEN (DE), PerkinElmer (US), F. Hoffmann-La Roche (CH), Macrogen (KR)
Segments CoveredApplication, End Use, Technology, Product Type, Service Type
Key Market OpportunitiesAdvancements in personalized medicine drive demand for Whole Exome Sequencing Market innovations and applications.
Key Market DynamicsTechnological advancements and regulatory changes drive competitive dynamics in the Whole Exome Sequencing Market.
Countries CoveredNorth America, Europe, APAC, South America, MEA

Market Highlights

Author
Kinjoll Dey
Research Analyst Level I

He is an extremely curious individual currently working in Healthcare and Medical Devices Domain. Kinjoll is comfortably versed in data centric research backed by healthcare educational background. He leverages extensive data mining and analytics tools such as Primary and Secondary Research, Statistical Analysis, Machine Learning, Data Modelling. His key role also involves Technical Sales Support, Client Interaction and Project management within the Healthcare team. Lastly, he showcases extensive affinity towards learning new skills and remain fascinated in implementing them.

Get In Touch
Leave a Comment

FAQs

What is the projected growth of the Whole Exome Sequencing market?

The Whole Exome Sequencing market is the expected increase in total market value of 16.38 USD billion over a defined forecast period 2025–2035. It is driven by factors such as demand trends, technological advances, regulatory changes, and geographic expansion.

What is the size of the Whole Exome Sequencing market?

Whole Exome Sequencing market size was valued at approximately 2.16 billion USD in 2024. This figure will reach 16.38 billion USD covering all regions (America, Europe, Asia, MEA and ROW), focusing its segments / services / distribution channels till 2035.

What is the CAGR of the Whole Exome Sequencing market?

Whole Exome Sequencing market is expected to grow at a CAGR of 20.2% between 2025 and 2035.

How much will the Whole Exome Sequencing market be worth by 2035?

Whole Exome Sequencing market is expected to be worth of 16.38 billion USD, reflecting growth driven by usage, technology and global demands by the end of 2035.

How will the Whole Exome Sequencing market perform over the next 10 years?

Over the next 10 years the Whole Exome Sequencing market is expected to shift from usd billion 2.16 to 16.38 billion USD, led by adoption of advanced tech, demographic trends, regulatory approvals, with potential headwinds from 2025 to 2035.

Which region held the largest market share in the Whole Exome Sequencing market?

North America had the largest share of the market

Download Free Sample

Kindly complete the form below to receive a free sample of this Report

Customer Stories
Case Study
Aerospace & Defense
Future of Dismounted Soldier Systems Market Trends & Adoption Roadmap 2019–2035

Compare Licence

×
Features License Type
Single User Multiuser License Enterprise User
Price $4,950 $5,950 $7,250
Maximum User Access Limit 1 User Upto 10 Users Unrestricted Access Throughout the Organization
Free Customization ✓ ✓ ✓
Direct Access to Analyst ✓ ✓ ✓
Deliverable Format ✓ ✓ ✓
Platform Access ✗ ✗ ✓
Discount on Next Purchase 10% 15% 15%
Printable Versions ✗ ✗ ✓